Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in First Line Treatment of Metastatic or Unresectable GIST
NCT00756509Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Best Overall Response at 6 months. Started Aug 2008; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00756509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00756509.